| |
With a 60+ year legacy of excellence in bioscience manufacturing, Puerto Rico is a hub for groundbreaking discoveries in the region & beyond. Local talent, tax benefits & the island's decades of expertise fuel companies like CytoImmune & OcyonBio. Learn more. 
|
|
Today’s Big NewsFeb 2, 2024 |
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
| By Andrea Park That brings the total number of medical device reports received since April 2021 to more than 116,000, with 561 reported deaths. |
|
|
|
By Annalee Armstrong Regeneron wants to improve on obesity care with a muscle-preservation approach, while elsewhere, the biopharma charts a new course in cell therapy thanks to the acquisition of 2seventy's pipeline. |
By Fraiser Kansteiner Sales of Humira—which once sat pretty as the world’s best-selling drug—plunged nearly 41% to $3.3 billion in the third quarter. |
By Max Bayer Bristol Myers Squibb is focused on integrating its new acquisitions, but CEO Chris Boerner said there's still interest in more development, which likely would center on bolt-on deals. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
By Angus Liu Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting for Bristol Myers' Abecma and J&J's Carvykti. |
By Gabrielle Masson After resigning from her role as medical officer at CRISPR Therapeutics, Phuong Khanh Morrow, M.D., is taking on the role of senior vice president and head of oncology therapeutic area unit at Takeda. |
By Conor Hale Edwards Lifesciences has claimed the FDA’s first approval of a transcatheter replacement implant for a leaky tricuspid heart valve three months after garnering a green light in Europe. |
By Nick Paul Taylor Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday, when the drugmaker axed a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from its R&D pipeline. |
By James Waldron In a second busy week of biotech IPOs, Alto Neuroscience and Fractyl Health will both be jumping onto the public markets this morning with their sights set on raking in over $100 million each. |
By Andrea Park For the second time just this week, an artificial intelligence-powered tool aimed at improving cervical cancer screening is taking center stage. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now. 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
